

Esther Zorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8908353/publications.pdf>

Version: 2024-02-01

30

papers

863

citations

759233

12

h-index

501196

28

g-index

34

all docs

34

docs citations

34

times ranked

1541

citing authors

#	ARTICLE	IF	CITATIONS
1	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2440-2451.	2.8	340
2	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. <i>European Heart Journal</i> , 2018, 39, 1784-1793.	2.2	94
3	Paradoxical Effect of Increased Diastolic Ca ²⁺ Release and Decreased Sinoatrial Node Activity in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2012, 126, 392-401.	1.6	77
4	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. <i>European Heart Journal</i> , 2022, 43, 3053-3067.	2.2	41
5	Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease. <i>Liver International</i> , 2016, 36, 1221-1229.	3.9	39
6	Clinical Profile of Cardiac Involvement in Danon Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e003117.	3.6	29
7	An International Multicenter Cohort Study on β -Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2022, 145, 333-344.	1.6	28
8	RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism. <i>JCI Insight</i> , 2017, 2, .	5.0	24
9	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 302, 124-130.	1.7	23
10	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. <i>Cardiovascular Research</i> , 2022, 118, 1466-1478.	3.8	20
11	Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation. <i>Circulation Research</i> , 2021, 129, e35-e52.	4.5	19
12	Thickness and an Altered miRNA Expression in the Epicardial Adipose Tissue Is Associated With Coronary Heart Disease in Sudden Death Victims. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 30-39.	0.6	11
13	Non-ventricular, Clinical, and Functional Features of the RyR2R420Q Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq1 1 07.84314 rg5T /Overline		
14	Left Dominant Arrhythmogenic Cardiomyopathy Caused by a Novel Nonsense Mutation in Desmoplakin. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 530-534.	0.6	8
15	Una nueva mutación en el gen del receptor de la rianodina (RyR2 C2277R) como causa de taquicardia ventricular polimórfica catecolaminérgica. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 71-73.	1.2	8
16	Miocardiopatía no compactada familiar asociada con una mutación nueva en el gen de la alfa-actina cardíaca. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 857-859.	1.2	7
17	A New Mutation in the Ryanodine Receptor 2 Gene (RYR2 C2277R) as a Cause Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 71-73.	0.6	7
18	Arrhythmogenic cardiomyopathy with left ventricular involvement versus ischemic heart disease: lessons learned from the family study and the reviewed autopsy of a young male. <i>Forensic Sciences Research</i> , 2019, 4, 274-279.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Left ventricular myocardial dysfunction in arrhythmogenic cardiomyopathy with left ventricular involvement: A door to improving diagnosis. International Journal of Cardiology, 2019, 274, 237-244.	1.7	7
20	Impact of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	3.1	6
21	Familial Left Ventricular Noncompaction Associated With a Novel Mutation in the Alpha-cardiac Actin Gene. Revista Espanola De Cardiologia (English Ed), 2014, 67, 857-859.	0.6	4
22	Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. Frontiers in Pharmacology, 2020, 11, 580481.	3.5	4
23	Flecainide, a Therapeutic Option in a Patient With Long QT Syndrome Type 3 Caused by the Heterozygous V411M Mutation in the SCN5A Gene. Revista Espanola De Cardiologia (English Ed), 2012, 65, 1058-1059.	0.6	2
24	Classification model based on strain measurements to identify patients with arrhythmogenic cardiomyopathy with left ventricular involvement. Computer Methods and Programs in Biomedicine, 2020, 188, 105296.	4.7	1
25	Cardiac phenotype in glycogen storage disease type XV: a rare cardiomyopathy to bear in mind. Revista Espanola De Cardiologia (English Ed), 2021, 74, 99-101.	0.6	1
26	Sensitivity and Negative Predictive Value of Treadmill Exercise Stress Testing for the Diagnosis of Catecholaminergic Polymorphic Ventricular Tachycardia. Response. Revista Espanola De Cardiologia (English Ed), 2015, 68, 546-547.	0.6	0
27	El trasfondo genético de la hipertrabeculación/miocardiopatía no compactada ventricular izquierda sigue sin estar claro. Respuesta. Revista Espanola De Cardiologia, 2015, 68, 167-168.	1.2	0
28	The Genetic Background of Left Ventricular Hypertrabeculation/Noncompaction Remains Vague. Response. Revista Espanola De Cardiologia (English Ed), 2015, 68, 167-168.	0.6	0
29	Sensibilidad y valor predictivo negativo de la ergometría para el diagnóstico de la taquicardia ventricular polimórfica catecolaminérica. Respuesta. Revista Espanola De Cardiologia, 2015, 68, 546-547.	1.2	0
30	Fenotipo cardiológico de la glucogenosis tipo XV: una miocardiopatía muy infrecuente a tener en cuenta. Revista Espanola De Cardiologia, 2021, 74, 99-101.	1.2	0